Biotechnology University Spin-Off Law In Russia

1. Introduction

Biotechnology University Spin-Off Law in Russia concerns the legal framework governing the creation, financing, ownership, commercialisation and regulation of biotechnology companies established using scientific research, intellectual property, laboratories, inventions or technological developments originating in Russian universities and research institutions.

A university spin-off is a commercial enterprise established to transform university research into marketable products and services. In biotechnology, these businesses may develop:

Genetic engineering and gene-editing technologies.

Pharmaceutical products and vaccines.

Cell and tissue engineering.

Molecular diagnostics and genetic testing.

Agricultural biotechnology and genetically modified organisms.

Biopharmaceuticals and biosimilars.

Medical devices and laboratory technologies.

Artificial biology and synthetic biology applications.

Russian law does not establish one comprehensive statute exclusively governing biotechnology university spin-offs. Instead, several areas of law operate together, particularly intellectual property, university innovation, corporate law, technology transfer, public research funding, pharmaceutical regulation, biosafety and commercial contracts.

The central legal challenge is balancing three interests: the university's ownership of publicly funded research, the researcher's rights as an inventor, and the spin-off company's ability to commercialise the technology.

2. Constitutional and legislative foundation

The Russian legal framework is principally based on the following legislation.

A. Constitution of the Russian Federation

Article 44 protects freedom of scientific, technical and artistic creativity and recognises intellectual property protection.

Its importance includes:

Protecting scientific research and academic creativity.

Supporting innovation and technological development.

Providing a constitutional foundation for intellectual property rights.

Supporting the lawful commercial exploitation of scientific discoveries.

B. Civil Code of the Russian Federation

The Civil Code, particularly Part IV, is central to university spin-off operations.

Important provisions include:

Article 1225: Recognised results of intellectual activity and means of individualisation.

Article 1228: Authorship of intellectual property.

Article 1232: State registration of certain intellectual property rights.

Article 1259: Copyright protection.

Article 1345: Patent rights.

Article 1350: Patentability of inventions.

Article 1354: Scope of patent protection.

Article 1370: Service inventions.

Article 1371: Inventions created under a contract.

Article 1372: Inventions created while performing work under a contract.

Article 1465: Trade secrets and know-how.

These provisions determine whether biotechnology inventions belong to researchers, universities or commercial companies.

C. Federal Law No. 217-FZ of 2 August 2009

This is one of the most important laws for university spin-offs.

It amended several Russian legislative acts to enable budgetary scientific institutions and higher educational institutions to establish business entities for the practical application (implementation) of intellectual activity results.

Its significance includes:

Enabling eligible public research institutions and universities to participate in commercial innovation companies.

Facilitating the practical application of university-owned research results.

Creating a legal route for scientific discoveries to enter the commercial market.

Supporting cooperation between researchers, universities and private investors.

The law is particularly important because it provides a statutory foundation for university-linked technology commercialisation.

D. Federal Law No. 127-FZ of 23 August 1996

The Federal Law on Science and State Scientific and Technical Policy establishes the general framework for scientific research, state scientific policy, research institutions and innovation activity.

E. Federal Law No. 273-FZ of 29 December 2012

The Education Law governs higher educational institutions, their activities, autonomy, research functions and participation in innovation-related activities.

Together, these laws establish the institutional and commercial foundations for Russian university spin-offs.

3. Federal Law No. 217-FZ and university spin-off formation

Federal Law No. 217-FZ is the foundation of the Russian university spin-off model.

Before its introduction, public universities and research institutions faced substantial restrictions in directly commercialising intellectual property developed through publicly funded scientific research.

The legislation created a mechanism through which eligible institutions could establish commercial entities to apply research results in practical economic activities.

Main legal requirements and considerations

Eligible founders: Qualifying budgetary scientific institutions and higher educational institutions may participate in establishing commercial companies.

Intellectual property contribution: Research results must satisfy the applicable statutory conditions for commercialisation.

Corporate structure: The spin-off may operate through an appropriate company structure, commonly a limited liability company.

University participation: The institution's participation must comply with the ownership and contribution rules applicable under the legislation.

Commercial activity: The company must undertake activities directed towards the practical application of the relevant intellectual property.

Documentation: The university should maintain appropriate records of ownership, contributions, licensing arrangements and the company's activities.

An important historical feature of the original framework was the minimum institutional participation requirement: 25% for joint-stock companies and one-third for limited liability companies in the relevant circumstances. These figures should not be treated as a universal statement of every current ownership arrangement without checking subsequent amendments and the particular institution's legal status.

The World Bank's analysis of Russian innovation policy documented the early operation of this framework and identified difficulties concerning sublicensing and the commercialisation of university-owned intellectual property.

World Bank+1

 

4. Intellectual property ownership in biotechnology spin-offs

Intellectual property is often the most valuable asset of a biotechnology spin-off.

For example, a university research team may develop a new genetically engineered protein, a vaccine platform or a diagnostic method. The company may then require patent rights to manufacture, license and distribute the technology.

Russian law distinguishes between authorship and ownership of exclusive intellectual property rights.

A. Researcher ownership

Under Article 1228 of the Civil Code, the natural person who creates an intellectual result through creative work is recognised as its author.

The researcher retains personal authorship rights even where the economic rights belong to the university.

B. University ownership

Article 1370 governs service inventions.

Where a university employee develops an invention within their employment duties or under a specific employer assignment:

The researcher retains authorship.

The employer generally holds the exclusive right and right to obtain a patent.

The researcher may have a statutory entitlement to remuneration.

Contractual arrangements may modify certain aspects of the default allocation.

This distinction is particularly important where university professors, laboratory scientists and doctoral researchers contribute to biotechnology patents.

C. Spin-off ownership

A university spin-off does not automatically become the owner of every invention developed by its founders.

The company must establish its rights through a legally valid mechanism, such as:

Assignment of exclusive rights.

A patent licence.

A research and development agreement.

A technology-transfer agreement.

A properly documented contribution permitted under the applicable university spin-off legislation.

D. Joint ownership

Biotechnology research frequently involves several institutions, laboratories and commercial partners.

Where different researchers or institutions contribute to an invention, ownership and commercial exploitation must be determined by the applicable contracts and Civil Code provisions.

Article 1229 is especially important because it regulates the exercise of jointly held exclusive rights.

5. Patent protection for biotechnology inventions

The Russian Civil Code provides patent protection for qualifying biotechnology inventions.

Article 1350 establishes the general requirements for patentability:

Novelty.

Inventive step.

Industrial applicability.

Potentially patentable biotechnology inventions include:

Genetically engineered microorganisms.

Recombinant proteins.

Certain engineered biological compositions.

New pharmaceutical formulations.

Biotechnological manufacturing processes.

Diagnostic technologies satisfying applicable patentability requirements.

However, not every biological discovery is patentable.

A naturally occurring biological material merely discovered in nature does not automatically qualify as a patentable invention. Claims involving biological materials, gene sequences and biological processes must satisfy the relevant statutory exclusions and patentability requirements.

The spin-off must also consider patent territoriality. A Russian patent does not automatically provide equivalent protection in the European Union, the United States or other jurisdictions.

6. University technology transfer and licensing

Technology transfer is the process through which scientific research becomes a commercially usable product or service.

In Russia, a university may transfer technology to its spin-off through an intellectual property licence or assignment, subject to the applicable statutory and institutional requirements.

The principal licensing arrangements include:

Licensing arrangementLegal significance
Exclusive licenceGives the company exclusive exploitation rights within the agreed scope
Non-exclusive licenceAllows the university to license the technology to multiple users
Patent assignmentTransfers the exclusive patent right
Know-how licencePermits use of confidential technical knowledge
Research collaborationEstablishes conditions for future research and resulting intellectual property

Articles 1235 and 1236 of the Civil Code are particularly relevant to licensing.

An important practical issue is whether the spin-off can sublicense its technology to pharmaceutical manufacturers, distributors or international partners.

The original ownership and licensing structure should therefore be examined before investment. A company that has access to a university patent but cannot lawfully sublicense it may face difficulties attracting investors and entering international markets.

OECD research on Russian public-research intellectual property commercialisation identifies the distinction between pre-existing institutional intellectual property and inventions developed after the spin-off is established.

OECD+1

 

7. Corporate structure, founders and investor rights

A university spin-off generally operates as a separate legal entity rather than as an ordinary university department.

The most common structure is an LLC (Obshchestvo s Ogranichennoy Otvetstvennostyu).

Its principal participants may include:

The university or research institution.

University scientists and inventors.

Private biotechnology entrepreneurs.

Venture-capital investors.

Pharmaceutical and medical-device companies.

Industrial research partners.

Important legal issues

A. Founders' agreements: These should establish capital contributions, voting rights, management responsibilities and ownership of intellectual property.

B. Shareholder disputes: Disagreements may concern company valuation, dilution, dividends, management control and the transfer of shares.

C. University governance: The university must comply with the statutory rules governing public property, institutional participation and financial management.

D. Investor protection: Investors should conduct due diligence on patent ownership, licence duration, research contracts, regulatory approvals and potential claims by researchers.

E. Corporate independence: The spin-off should maintain separate accounts, contracts, employees and operational records.

A university's participation as a shareholder does not mean that every laboratory asset or research result automatically becomes the company's property.

8. Biotechnology regulatory approvals

Establishing a spin-off does not automatically authorise it to manufacture or sell biotechnology products.

The company must comply with the regulatory framework applicable to its particular technology.

A. Pharmaceutical biotechnology

Federal Law No. 61-FZ of 12 April 2010, On the Circulation of Medicines, governs the development, testing, registration, manufacturing and circulation of medicinal products.

A university spin-off developing a recombinant protein, biological medicine, vaccine or biosimilar must consider:

Preclinical testing.

Clinical-trial requirements.

State registration.

Manufacturing standards.

Quality control.

Pharmacovigilance.

Post-market regulatory supervision.

The statutory framework also includes applicable Eurasian Economic Union requirements.

cis-legislation.com+2

 

B. Biomedical cellular products

Federal Law No. 180-FZ of 23 June 2016, On Biomedical Cellular Products, regulates the development, preclinical research, clinical trials, examination, registration, production and circulation of qualifying biomedical cellular products.

It is particularly relevant to spin-offs working with:

Cell-based therapeutic products.

Tissue-engineering technologies.

Regenerative medicine.

Cellular therapeutic platforms.

Patient-specific cellular products.

The company must determine whether its product falls within this law or another regulatory category. Certain gene-therapy medicines and high-technology medicinal products are subject to the medicines framework rather than the biomedical cellular product framework.

The Federal Service for Surveillance in Healthcare (Roszdravnadzor) publishes requirements concerning the licensing and supervision of biomedical cellular product manufacturing.

cis-legislation.com+2

 

C. Genetically engineered organisms

Federal Law No. 86-FZ of 5 July 1996, On State Regulation in the Field of Genetic Engineering Activities, is relevant to organisations undertaking regulated genetic engineering activities.

A biotechnology spin-off may need to consider:

Applicable registration and regulatory procedures.

Laboratory safety standards.

Containment requirements.

Environmental protection.

Handling and transportation of biological materials.

Personnel training and safety documentation.

D. Medical devices

Where a spin-off develops genetic diagnostic equipment, laboratory instruments or biotechnology-based medical devices, it must determine the applicable medical-device classification and registration requirements.

E. Human biological materials

Research involving human cells, tissues and genetic materials raises additional questions concerning informed consent, confidentiality, research ethics and the lawful use of biological samples.

The company cannot assume that a university's original research consent automatically authorises subsequent commercial use.

9. Public research funding and government grants

Russian university spin-offs may receive financial support through research grants, innovation programmes, government contracts and other funding arrangements.

However, the source of funding can determine who owns the resulting intellectual property.

For example, a university may receive government funding to develop a new vaccine platform. A commercial spin-off may subsequently be established to manufacture the product.

The parties must determine:

Whether the research was publicly funded.

Who owns the resulting patent.

Whether the government retains specific rights.

Whether the university may transfer or license the technology.

Whether the company must satisfy funding conditions.

Whether the technology can be commercialised internationally.

Federal Law No. 127-FZ and the Civil Code provisions concerning inventions created under contracts are important in this context.

Article 1371 is particularly relevant to inventions developed while performing research and development contracts.

The contractual allocation of patent rights must be examined carefully. A spin-off cannot simply assume that the research institution has unrestricted authority to transfer every government-funded invention.

10. Trade secrets, confidential research and employee mobility

Biotechnology companies often possess valuable information that cannot or should not be disclosed publicly.

Examples include:

Genetic engineering protocols.

Cell-culture methods.

Manufacturing processes.

Research databases.

Experimental results.

Proprietary laboratory procedures.

Drug-development information.

Article 1465 of the Civil Code governs know-how.

Federal Law No. 98-FZ of 29 July 2004, On Commercial Secrets, provides an additional framework for protecting confidential commercial information.

A spin-off should establish:

Confidentiality agreements.

Employee intellectual property clauses.

Laboratory access controls.

Research-data protection policies.

Confidentiality provisions in university collaboration agreements.

Procedures for the return or destruction of confidential material.

The distinction between a patent and a trade secret is important. A patent requires public disclosure of the claimed invention, whereas know-how protection depends on maintaining legally protected confidentiality.

11. International technology transfer and foreign investment

Russian biotechnology spin-offs may seek international investors, foreign research partners and overseas pharmaceutical manufacturers.

International transactions create additional legal questions concerning:

Patent protection in foreign jurisdictions.

Export controls and sanctions compliance.

Transfer of biological materials.

Cross-border genetic-data transfers.

International clinical research.

Foreign ownership and investment restrictions.

International licensing and royalty payments.

Federal Law No. 57-FZ of 29 April 2008, On the Procedure for Foreign Investments in Business Entities of Strategic Importance for National Defence and State Security, may become relevant where a company conducts activities covered by its strategic-importance provisions.

Not every biotechnology company is automatically subject to this law. Its application depends on the company's actual activities and the statutory criteria.

Federal Law No. 152-FZ of 27 July 2006, On Personal Data, is also important where the company processes patient information, genetic information or identifiable research-participant data.

12. Case laws concerning university spin-offs and biotechnology commercialisation

Russian courts have developed relevant principles through intellectual property disputes, university research ownership disputes and pharmaceutical patent litigation.

An important qualification is necessary: there is no extensive body of reported Russian judgments exclusively concerning biotechnology university spin-off formation under Federal Law No. 217-FZ. The following decisions should therefore be distinguished between direct university intellectual property precedents and related pharmaceutical biotechnology precedents.

Case 1. ITMO University v. Institute of Chemistry of Silicates – Case No. SIP-635/2020

Direct university IP relevance

Court: Russian Intellectual Property Court.

Decision: 30 March 2021, upheld by the Presidium on 6 August 2021.

Case: SIP-635/2020; Presidium No. S01-1044/2021.

Subject: Ownership of a jointly patented invention.

Facts

The National Research University ITMO challenged the inclusion of the Institute of Chemistry of Silicates of the Russian Academy of Sciences as a patent holder.

The patent concerned a method of manufacturing a micro-optical grating.

Researchers from both institutions participated in the work. The dispute involved their employment relationships, a scientific cooperation agreement and a separate agreement governing patenting and use of the invention.

ITMO argued that the invention had been created through the performance of a government contract and that the other institution should not have been named as a patent holder.

Legal issue

Whether the university could establish exclusive ownership merely by asserting that the invention arose from publicly funded research.

Judicial significance

The court did not accept the university's claim to remove the other institution as patent holder.

The evidence showed that researchers from both institutions participated in the development under their employment functions and that the parties had entered into agreements governing cooperation and patenting.

The university had not sufficiently established its argument concerning the alleged government-contract basis for exclusive ownership.

Relevance to biotechnology spin-offs

This decision is particularly important where a biotechnology company originates from collaborative university research.

For example, a university may collaborate with an independent medical research institute to develop a cellular treatment or genetic diagnostic method.

If the parties do not clearly establish ownership and patenting arrangements, the resulting intellectual property may become the subject of institutional litigation.

Principle: Scientific collaboration, employment relationships and contractual documentation must be examined together when determining patent ownership.

ГАРАНТ+1

 

Case 2. Nativa LLC v. Celgene Corporation – Lenalidomide patent dispute

Case No.: A40-71471/2017.

Court: Moscow Arbitration Court and subsequent judicial review.

Subject: Pharmaceutical patent rights and compulsory licensing.

Relevant provision: Article 1362 of the Civil Code.

Facts

The dispute concerned Celgene's patent protection relating to lenalidomide, a pharmaceutical substance used in cancer treatment.

Nativa sought a compulsory licence in connection with the commercial development of a pharmaceutical product.

Legal issue

Whether the statutory conditions for compulsory licensing were satisfied despite the existence of another company's patent rights.

Significance

The litigation illustrates the relationship between patent exclusivity, dependent inventions and access to pharmaceutical technology.

Relevance to university spin-offs

A university spin-off may develop a new therapeutic formulation or manufacturing process that depends on technology protected by another patent.

It must assess freedom to operate before commercialising the product.

This case is a pharmaceutical patent precedent, not a direct judgment about university spin-off ownership.

Law Gratis+1

 

Case 3. Sugen LLC and Pharmacia & Upjohn v. Nativa LLC – Sunitinib patent dispute

Case No.: A40-166505/2017.

Subject: Pharmaceutical patent infringement and compulsory licensing.

Relevant provision: Article 1362 of the Civil Code.

Supreme Court review: 20 February 2020.

Facts

The dispute concerned patent rights relating to sunitinib and the commercialisation of a pharmaceutical product by Nativa.

The defendant sought a compulsory licence while patent infringement proceedings were underway.

Legal issue

Whether compulsory licensing could be justified under the applicable statutory requirements.

Significance

The proceedings demonstrate that patent exclusivity is not absolute and must be considered within the statutory compulsory-licensing framework.

Relevance to biotechnology

A university spin-off developing a biotechnology-derived medicine should examine:

Existing patent rights.

Dependent inventions.

Licensing opportunities.

Compulsory licensing conditions.

Potential infringement liability.

The case concerns pharmaceutical technology rather than a university-created biological invention.

Law Gratis+1

 

Case 4. Russian Supreme Court – Remdesivir Decision

Pharmaceutical IP precedent

Court: Supreme Court of the Russian Federation.

Date: 27 May 2021.

Case No.: AKPI21-303.

Subject: Patent rights and government-authorised use of patented pharmaceutical technology.

Facts and legal issue

The proceedings concerned the legal framework for the use of patented pharmaceutical technology in Russia and the relationship between exclusive patent rights and statutory exceptions.

Judicial significance

The Supreme Court examined the relationship between Articles 1229, 1231 and 1346 of the Civil Code and the territorial protection of patent rights.

The decision illustrates that exclusive patent rights must be understood alongside statutory exceptions permitting certain uses without the right holder's consent.

Relevance to university spin-offs

A biotechnology spin-off must understand that patent ownership does not guarantee unrestricted commercial exploitation. Government-authorised use and other statutory exceptions may affect its commercial strategy.

This is a related pharmaceutical patent decision, not a direct university spin-off judgment.

Case No. АКПИ21-303

 

Case 5. Intellectual Property Court – Service Invention and Institutional Ownership

Court: Russian Intellectual Property Court.

Date: 6 August 2021.

Case No.: S01-1044/2021.

Underlying case: SIP-635/2020.

Legal principle

The court's reasoning confirms the importance of Article 1370 of the Civil Code in determining the ownership of inventions created by employees in the course of their employment duties.

The researcher remains the inventor, while the employer generally receives the exclusive economic rights to a qualifying service invention.

Relevance

A biotechnology spin-off should investigate whether its founders' inventions were created:

During university employment.

Under a university research assignment.

Through a government-funded research project.

Under a collaboration agreement.

Using another institution's research resources.

The company must obtain valid rights before exploiting the invention commercially.

ГАРАНТ+1

 

13. Liability of university biotechnology spin-offs

A biotechnology spin-off may face civil, administrative and, in appropriate circumstances, criminal liability.

Type of liabilityExamples
Intellectual propertyPatent infringement and unauthorised use of know-how
ContractualBreach of university licensing agreements
Product liabilityDefective or unsafe biotechnology products
RegulatoryManufacturing without required authorisation
EnvironmentalUnlawful release of regulated biological materials
EmploymentDisputes over inventor remuneration
Data protectionUnlawful processing of genetic and medical information
CorporateMisuse of university assets or breach of directors' duties

The company may also face disputes over inaccurate research claims, improper clinical-trial practices and failures to comply with product safety requirements.

14. Major legal challenges

Russian biotechnology university spin-offs face several important structural challenges.

1. Ownership uncertainty: Research may involve several universities, public institutions and individual scientists.

2. Technology-transfer difficulties: A company may receive a licence that does not provide sufficient commercial control.

3. Researcher remuneration: Disputes may arise over inventor compensation and royalty arrangements.

4. Funding limitations: Early-stage biotechnology companies require substantial capital for preclinical research, clinical testing and manufacturing.

5. Regulatory complexity: Different products may fall under different pharmaceutical, cellular-product, medical-device or genetic-engineering frameworks.

6. Patent infringement: A new product may depend on inventions protected by third-party patents.

7. International commercialisation: Foreign licensing, sanctions compliance and cross-border technology transfer can complicate market expansion.

8. University governance: Public research institutions must comply with rules concerning institutional assets, public funding and corporate participation.

15. Practical example: Establishing a Russian university biotechnology spin-off

Consider a hypothetical Russian university that develops a new genetically engineered protein for treating a serious disease.

Illustrative commercialisation process

Scientific discovery

University researchers develop the engineered protein.

Intellectual property assessment

The university identifies inventors, service inventions, patentability and ownership.

Spin-off formation

An eligible institution establishes a commercial company under the applicable university spin-off framework.

Technology transfer

The company obtains an appropriate patent assignment or licence.

Investment

Private investors contribute capital under shareholder and investment agreements.

Regulatory approval

The company undertakes the necessary preclinical studies, clinical trials and medicine-registration procedures.

Manufacturing and commercialisation

The company obtains the necessary manufacturing authorisations and begins lawful commercial distribution.

The company must comply with intellectual property, corporate, pharmaceutical, research ethics and biosafety legislation throughout this process.

16. Recommendations for strengthening Russian university spin-off law

Several legal and institutional reforms could improve biotechnology commercialisation:

Develop clearer rules for transferring university-owned patents to spin-off companies.

Establish transparent inventor remuneration and royalty-sharing mechanisms.

Improve standard university technology-transfer agreements.

Clarify ownership of inventions produced through multi-institutional research.

Strengthen university technology-transfer offices.

Improve access to early-stage biotechnology investment.

Establish clear procedures for commercialising publicly funded biological research.

Improve regulatory guidance for cellular therapies and genetically engineered products.

Strengthen contractual protection of research data and confidential know-how.

Improve international cooperation in patent protection and biotechnology research.

17. Conclusion

Biotechnology University Spin-Off Law in Russia represents the intersection of scientific innovation, intellectual property, corporate governance, public research funding and biotechnology regulation.

Federal Law No. 217-FZ provides an important statutory foundation for eligible universities and research institutions to establish commercial entities for applying intellectual property results. The Civil Code determines the ownership, licensing and protection of inventions, while Federal Laws Nos. 61-FZ and 180-FZ regulate important categories of biotechnology products.

The ITMO University litigation, Case No. SIP-635/2020, is particularly significant because it demonstrates how disputes concerning collaborative research, service inventions and institutional patent ownership can affect commercialisation.

The pharmaceutical patent cases involving Nativa further illustrate the importance of patent exclusivity, freedom to operate and compulsory licensing.

Ultimately, the success of a Russian biotechnology university spin-off depends not merely on scientific discovery, but on establishing legally secure intellectual property ownership, transparent institutional relationships, adequate financing and compliance with product-specific regulatory requirements.

18. Important legislation and research references

Legislation / authoritySubject
Russian Constitution, Article 44Scientific creativity and intellectual property
Federal Law No. 217-FZ (2009)University spin-off formation
Federal Law No. 127-FZ (1996)Science and scientific policy
Federal Law No. 273-FZ (2012)Education and universities
Civil Code, Part IVIntellectual property
Federal Law No. 98-FZ (2004)Commercial secrets
Federal Law No. 61-FZ (2010)Pharmaceutical products
Federal Law No. 180-FZ (2016)Biomedical cellular products
Federal Law No. 86-FZ (1996)Genetic engineering
Federal Law No. 152-FZ (2006)Personal data
Federal Law No. 57-FZ (2008)Foreign investment in strategic entities

Useful official and research sources:

Rospatent – Civil Code of the Russian Federation, Part IV.

ITMO University v. Institute of Chemistry of Silicates – Case SIP-635/2020.

Roszdravnadzor – Biomedical Cellular Products.

Federal Law No. 61-FZ – Circulation of Medicines.

OECD – Protection and Commercialisation of Intellectual Property Created by Russian Public Research Organisations.

World Bank – Russian Innovation and Commercialisation Policy Research.

Academic qualification: The cited cases provide relevant judicial principles, but most are not direct decisions on biotechnology university spin-off formation. The legal analysis distinguishes direct university IP litigation from analogous pharmaceutical patent disputes. Russian legislation and amendments should be checked against the official text applicable on the date of the transaction.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT